VIDEO
Video abstract Beck.mp4 (100.11 MB)
DOCUMENT
Graphical Abstract.pdf (5.34 MB)
PRESENTATION
Plain Language Summary.pptx (162.34 kB)
1/0
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Version 2 2022-05-11, 22:37
Version 1 2022-05-02, 20:14
media
posted on 2022-05-11, 22:37 authored by Adis Journals on behalf of:, Lisa Beck, Mette Deleuran, Robert Bissonnette, Marjolein de Bruin-Weller, Ryszard Galus, Takeshi Nakahara, Seong Jun Seo, Faisal A. Khokhar, Jignesh Vakil, Jing Xiao, Ainara Rodriguez Marco, Noah A. Levit, John T. O’Malley, Arsalan Shabbir© The authors, CC-BY-NC 2022
The above video abstract, graphical abstract and plain language summary represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite)..
